Beneficial Effects of Paraffin Bath Therapy as Additional Treatment of Chronic Hand Eczema: A Randomized, Single-Blind, Active-Controlled, Parallel-Group Study

被引:3
|
作者
Waked, Intsar S. [2 ]
Ibrahim, Zizi M. [1 ,2 ]
机构
[1] Princess Nourah Bint Abdulrahman Univ, Rehabil Sci Dept, Coll Hlth & Rehabil Sci, Riyadh 11671, Saudi Arabia
[2] Cairo Univ, Fac Phys Therapy, Dept Phys Therapy Surg, Giza, Egypt
关键词
paraffin bath therapy; hand eczema; SCORing Atopic Dermatitis (SCORAD); dermatology life quality index; itching; QUALITY-OF-LIFE; ATOPIC-DERMATITIS; MOBILIZATION TECHNIQUES; SCORAD INDEX; WAX BATHS; FOLLOW-UP; POPULATION; SEVERITY; VALIDATION; GUIDELINES;
D O I
10.1089/acm.2020.0356
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective: Chronic hand eczema (CHE) is a common inflammatory skin disease with a major psychological and socioeconomic impacts on patients' quality of life (QoL) and work ability. To the best of knowledge, this study is the first randomized-controlled trial conducted to evaluate the effect of paraffin bath therapy in management of hand eczema and its related symptoms. Design: This study was a parallel-group, active-control, randomized clinical trial with measures at pretreatment, 6th week, and 12th week of treatment. Settings: The study took place at the Outpatient Clinic of Faculty of Physical Therapy, Cairo University, and some licensed rehabilitation centers in Cairo for a 1-year period. Subjects: Sixty patients with moderate to severe CHE were randomly assigned into two groups of equal number; the paraffin bath therapy group and the control group. Interventions: The paraffin group received paraffin bath therapy for 5 days a week for 12 weeks, in addition to the routine skin care program, while the control group only received the routine skin care program. Outcome measures: SCORing Atopic Dermatitis (SCORAD) was used to assess the severity of atopic dermatitis and dermatology life quality index (DLQI) to assess the effect of CHE on quality of patients' life. All measurements were obtained before, at the 6th week, and at the 12th week of treatment. Results: Marked improvement in the severity of the disease symptoms was observed, reflected by a highly decrease in objective SCORAD score in the paraffin group over time more than the control group. The percentage of reduction was 28.6% in paraffin group versus 0.41% in control group. Subjective item score (itching and sleepiness) was reduced in the paraffin group more than the control group with a percentage of improvement (47% and 5.5%), respectively. Regarding QoL measure, there were highly positive changes in DLQI in paraffin group more than the control group. The percentage of improvement was 60% in paraffin group and 3.8% in control group. Conclusions: Paraffin bath therapy applied for a 12-week duration seems to be effective, both in reducing severity of eczema symptoms and improving QoL in patients with CHE.
引用
收藏
页码:1144 / 1150
页数:7
相关论文
共 50 条
  • [21] Efficacy and safety of supramolecular active zinc in the treatment of scalp psoriasis: a multicentre, randomized, observed-blind, parallel-group, placebo- and active-controlled noninferiority trial
    Yu, Chen
    Yu, Nan
    Jiang, Xian
    Gao, Xinghua
    Lv, Shichao
    Wang, Gang
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 48 (10) : 1138 - 1144
  • [22] Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Aliskiren in Healthy Chinese Subjects A Randomized, Single-Blind, Parallel-Group, Placebo-Controlled Study
    Hu, Pei
    Bartlett, Michael
    Karan, Rajesh S.
    Jiang, Ji
    Zhang, Shuyang
    Zhang, Jianyan
    Howard, Dan
    Yeh, Ching-Ming
    Al-Fayoumi, Suliman
    Jarugula, Venkateswar
    Dole, William P.
    CLINICAL DRUG INVESTIGATION, 2010, 30 (04) : 221 - 228
  • [23] Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Aliskiren in Healthy Chinese SubjectsA Randomized, Single-Blind, Parallel-Group, Placebo-Controlled Study
    Pei Hu
    Michael Bartlett
    Rajesh S. Karan
    Ji Jiang
    Shuyang Zhang
    Jianyan Zhang
    Dan Howard
    Ching-Ming Yeh
    Suliman Al-Fayoumi
    Venkateswar Jarugula
    William P. Dole
    Clinical Drug Investigation, 2010, 30 : 221 - 228
  • [24] A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar
    Wang, Yanli
    Liu, Zhengzhi
    Deng, Qiaohuan
    Su, Zhengjie
    Xue, Jinling
    Zhao, Yicheng
    Yang, Haimiao
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (11) : 849 - 855
  • [25] Three-Year Outcomes from BENEFIT, a Randomized, Active-Controlled, Parallel-Group Study in Adult Kidney Transplant Recipients
    Vincenti, F.
    Larsen, C. P.
    Alberu, J.
    Bresnahan, B.
    Garcia, V. D.
    Kothari, J.
    Lang, P.
    Mancilla Urrea, E.
    Massari, P.
    Mondragon-Ramirez, G.
    Reyes-Acevedo, R.
    Rice, K.
    Rostaing, L.
    Steinberg, S.
    Xing, J.
    Agarwal, M.
    Harler, M. B.
    Charpentier, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (01) : 210 - 217
  • [26] Randomized, parallel-group, double-blind, controlled study to evaluate the efficacy and safety of carbohydrate-derived fulvic acid in topical treatment of eczema
    Gandy, Justin J.
    Snyman, Jacques R.
    van Rensburg, Constance E. J.
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2011, 4 : 145 - 148
  • [27] Protocol for a Single-Blind, Randomized, Parallel-Group Study of a Nonpharmacological Integrated Care Intervention to Reduce the Impact of Breathlessness in Patients with Chronic Obstructive Pulmonary Disease
    Smith, Tracy A.
    Roberts, Mary M.
    Cho, Jin-Gun
    Klimkeit, Ester
    Luckett, Tim
    McCaffrey, Nikki
    Kirby, Adrienne
    Wheatley, John R.
    PALLIATIVE MEDICINE REPORTS, 2020, 1 (01): : 296 - 306
  • [28] Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial
    Calverley, Peter M. A.
    Anzueto, Antonio R.
    Carter, Kerstine
    Groenke, Lars
    Hallmann, Christoph
    Jenkins, Christine
    Wedzicha, Jadwiga
    Rabe, Klaus F.
    LANCET RESPIRATORY MEDICINE, 2018, 6 (05): : 337 - 344
  • [29] A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis
    Elewski, B.
    Pollak, R.
    Ashton, S.
    Rich, P.
    Schlessinger, J.
    Tavakkol, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (02) : 389 - 398
  • [30] A randomized, placebo- and active-controlled, parallel-group, multicenter, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis
    Elewski, Boni
    Tavakkol, Amir
    Pollak, Richard
    Ashton, Scott
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB76 - AB76